Disc Medicine received a Complete Response Letter (CRL) from FDA for its New Drug Application (NDA) for bitopertin as a treatment for erythropoietic protoporphyria (EPP), delaying a potential ...
As Black History Month approaches, discussions around identity, legacy, economics, and empowerment are gaining renewed attention. Not Who We Are contributes to this broader discourse by offering a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results